纳米孔靶向测序在分枝杆菌鉴定和耐药基因检测中的研究进展  

Research progress on nanopore-based targeted sequencing in identification of Mycobacterium tuberculosis and detection of drug-resistant genes

作　　者：杨晨 高卫卫[2] 郭羿成 曾谊 Yang Chen;Gao Weiwei;Guo Yicheng;Zeng Yi(School of Public Health,Nanjing Medical University,Nanjing 211166,China;Department of Tuberculosis,Affiliated Hospital of Nanjing University of Chinese Medicine/the Second Hospital of Nanjing/Nanjing Municipal Public Health Medical Center,Nanjing 210003,China)

机构地区：[1]南京医科大学公共卫生学院,南京211166 [2]南京中医药大学附属南京医院/南京市第二医院/南京市公共卫生医疗中心结核科,南京210003

出　　处：《中国防痨杂志》2024年第5期578-583,共6页Chinese Journal of Antituberculosis

摘　　要：2023年全球结核病报告显示,结核病的流行病学形势依然严峻。现有的检测方法在分枝杆菌菌种鉴定和耐药基因检测方面存在不足之处,临床亟需开发更加便捷、高效、准确的检测技术,以满足结核病早期诊断和指导治疗的需求。纳米孔靶向测序具有便捷高效、长读长测序等优势,给结核病和耐药结核病的诊疗带来了新的契机。笔者就纳米孔靶向测序这一新技术的原理与特点,以及在分枝杆菌鉴定和耐药基因检测方面的应用进行综述,旨在为临床工作者探索新技术提供参考。The Global Tuberculosis Report 2023 showed that the epidemiological situation of tuberculosis is still serious.The current detection methods exhibit limitations in accurately identifying mycobacterial species and detecting drug-resistant genes.There is an urgent need to develop clinically applicable detection technologies that are more convenient,efficient,and precise to adapt the needs for early diagnosis and treatment of tuberculosis.Nanopore sequencing presents a promising avenue with its inherent advantages of convenience,efficiency,long-read lengths,and extensive sequencing capabilities,thereby offering novel prospects for diagnosing and treating tuberculosis as well as drug-resistant strains.This paper provides a comprehensive review of the principles and characteristics of nanopore-based targeted sequencing along with its applications in mycobacterial identification and drug-resistant gene detection,aiming to provide references for clinical staff to explore the innovative technology.

关 键 词：分枝杆菌 结核 基因 诊断 

分 类 号：R52[医药卫生—内科学] R446.5[医药卫生—临床医学]